ライフサイエンスコーパス: poly(ADP ribose) polymerase

1 cision repair was blocked by an inhibitor of polyADP ribose polymerase.

2 e consisting of caspase-3 and -7 and cleaved poly(ADP)-ribose polymerase.

3 ch, in turn, activates the DNA repair enzyme poly(ADP)-ribose polymerase.

4 zed human cells to olaparib, an inhibitor of poly(ADP-ribose) polymerase.

5 tential pharmaceutical target tankyrase 1, a poly(ADP-ribose) polymerase.

6 hondria, caspase 3 activity, and cleavage of poly(ADP-ribose) polymerase.

7 caspase-3 and cleaved the caspase substrate poly(ADP-ribose) polymerase.

8 f apoptotic mediators, such as caspase-3 and poly(ADP-ribose) polymerase.

9 ncreased the expression of apoptotic cleaved poly(ADP-ribose) polymerase.

10 ious enzyme families, including sirtuins and poly(ADP-ribose) polymerases.

11 HR, but confers sensitivity to inhibition of poly(ADP-ribose) polymerases.

12 e polymers, thereby reversing the effects of poly(ADP-ribose) polymerases.

13 endent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases.

14 erases, including a subset commonly known as poly(ADP-ribose) polymerases.

15 eference as caspase-3, is better at cleaving poly(ADP ribose) polymerase 1 (PARP) and Hsp90 cochapero

16 nents of the topoisomerase IIbeta (TOP2beta)/poly(ADP ribose) polymerase 1 (PARP1) complex are necess

17 ingly, mtp53 depletion profoundly influenced poly(ADP ribose) polymerase 1 (PARP1) localization, with

18 ion, Rev1-deficiency is associated with high poly(ADP) ribose polymerase 1 (PARP1) activity, low endo

19 ing, whereas DNA repair pathways mediated by poly(ADP)ribose polymerase 1 (PARP1) serve as backups.

20 ing evidence shows that chromatin-associated poly(ADP-ribose) polymerase 1 (PARP-1) and its enzymatic

21 E4orf4 associates with the DNA damage sensor poly(ADP-ribose) polymerase 1 (PARP-1) and that the asso

22 role for NEDD8 in regulating the activity of poly(ADP-ribose) polymerase 1 (PARP-1) in response to ox

23 The success of poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors in can

24 Poly(ADP-ribose) polymerase 1 (PARP-1) is a cellular enz

25 Poly(ADP-ribose) polymerase 1 (PARP-1) is a multidomain

26 Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzy

27 Poly(ADP-ribose) polymerase 1 (PARP-1) is an abundant nu

28 ins DNA-dependent protein kinase (DNA-PK) or poly(ADP-ribose) polymerase 1 (PARP-1) prevented the DNA

29 B and SP1 bind to a composite element in the poly(ADP-ribose) polymerase 1 (PARP-1) promoter in a mut

30 ite and promote the rapid proteolysis of the poly(ADP-ribose) polymerase 1 (PARP-1), but the mechanis

31 ciation of E4orf4 with the DNA damage sensor poly(ADP-ribose) polymerase 1 (PARP-1).

32 ivates the central DNA damage sensor protein poly(ADP-ribose) polymerase 1 (PARP1) and activates casp

33 The anti-cancer drug target poly(ADP-ribose) polymerase 1 (PARP1) and its close homo

34 ically, we found that ZBTB24 associates with poly(ADP-ribose) polymerase 1 (PARP1) and stimulates its

35 Here, we identify poly(ADP-ribose) polymerase 1 (PARP1) as a novel DDB2-as

36 Here, we identify poly(ADP-ribose) polymerase 1 (PARP1) as a previously un

37 investigated the regulation of mitochondrial poly(ADP-ribose) polymerase 1 (PARP1) by the cyclic aden

38 Poly(ADP-ribose) polymerase 1 (Parp1) catalyzes poly(ADP

39 ation of caspase 3 and caspase 9, along with poly(ADP-ribose) polymerase 1 (PARP1) cleavage, which is

40 -molecule inhibitor of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP1) for the detection

41 The nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP1) has been shown to

42 response to a variety of cellular stresses, poly(ADP-ribose) polymerase 1 (PARP1) has vital roles in

43 er checkpoint kinase 1 (CHK1) inhibitors and poly(ADP-ribose) polymerase 1 (PARP1) inhibitors interac

44 Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were re

45 Furthermore, inhibition or silencing of poly(ADP-ribose) polymerase 1 (PARP1) inhibits PAR-media

46 Poly(ADP-ribose) polymerase 1 (PARP1) interacts genetica

47 n Xenopus egg extract assays, we showed that poly(ADP-ribose) polymerase 1 (PARP1) is modified by SUM

48 poly(ADP-ribosyl)ation mediated primarily by poly(ADP-ribose) polymerase 1 (PARP1) is responsible for

49 Here we show that the enzyme poly(ADP-ribose) polymerase 1 (PARP1) modifies PAP and r

50 ity in identifying ADP-ribosylation sites on Poly(ADP-ribose) Polymerase 1 (PARP1) with mass spectrom

51 h increased expression of DNA ligase 3alpha, poly(ADP-ribose) polymerase 1 (PARP1), and X-ray repair

52 Here, we have found that a host protein, poly(ADP-ribose) polymerase 1 (PARP1), facilitates IFNAR

53 -ribose (PAR) chains, primarily catalyzed by poly(ADP-ribose) polymerase 1 (PARP1), is crucial for ce

54 y also contain other factors, including PML, poly(ADP-ribose) polymerase 1 (PARP1), ligase IIIalpha,

55 Here, we report that a cellular protein, poly(ADP-ribose) polymerase 1 (PARP1), plays a critical

56 ng these, an important DNA damage regulator, poly(ADP-ribose) polymerase 1 (PARP1), was discovered.

57 e major enzyme that catalyses this reaction, poly(ADP-ribose) polymerase 1 (PARP1), were discovered m

58 apurinic/apyrimidinic endonuclease 1 (APE1), poly(ADP-ribose) polymerase 1 (PARP1), X-ray repair cros

59 protects replication forks from stalling at poly(ADP-ribose) polymerase 1 (PARP1)-DNA complexes trap

60 D(+)-dependent auto-poly-ADP-ribosylation of poly(ADP-ribose) polymerase 1 (PARP1).

61 poly(ADP-ribose) (PAR) is mediated mainly by poly(ADP-ribose) polymerase 1 (PARP1).

62 Poly(ADP-ribose) polymerase 1 (PARP1, also known as ARTD

63 , we found that recruitment was dependent on poly(ADP-ribose) polymerase 1 activity as well as Kdm4b

64 to and irreversibly inhibits the activity of poly(ADP-ribose) polymerase 1, an important anticancer t

65 oskeleton while promoting the degradation of poly(ADP-ribose) polymerase 1, an inhibitor of osteoclas

66 hat the SNAT2 ER-alpha-ERE complex contained poly(ADP-ribose) polymerase 1, Lupus Ku autoantigen prot

67 t assay, quantification of 8-oxoguanine, and poly(ADP-ribose) polymerase 1.

68 ers, including cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase 1.

69 Poly(ADP-ribose)polymerase 1 (PARP-1) is a key eukaryoti

70 Here, we demonstrate that the nuclear enzyme Poly(ADP-ribose)Polymerase 1 (PARP1) is a promising targ

71 e, lack of hepatocyte HMGB1 led to excessive poly(ADP-ribose)polymerase 1 activation, exhausting nico

72 ion of caspases 3, 7, 8, and 9 and inhibited poly(ADP-ribose)polymerase 1 cleavage and DNA fragmentat

73 Inhibition of polyADP-ribose polymerase 1 (PARP-1) suppressed the nucl

74 large Ca(2+) and Na(+) influx, activation of poly(ADP ribose) polymerase-1 (PARP-1), and delayed Ca(2

75 ecting parthanatos, monitored by cleavage of poly(ADP ribose)polymerase-1 (PARP-1), or necroptosis, a

76 combination of LuTate and the small molecule Poly(ADP-ribose) polymerase-1 (PARP) inhibitor, talazopa

77 Poly(ADP-ribose) polymerase-1 (PARP-1) (ADP, adenosine d

78 Neuronal poly(ADP-ribose) polymerase-1 (PARP-1) activation in dia

79 ze nuclear LXRalpha complexes and identified poly(ADP-ribose) polymerase-1 (PARP-1) as an LXR-associa

80 Poly(ADP-ribose) polymerase-1 (PARP-1) creates the postt

81 This work focuses on the regulation of poly(ADP-ribose) polymerase-1 (PARP-1) expression by MKP

82 The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-establ

83 Interest in nuclear imaging of poly(ADP-ribose) polymerase-1 (PARP-1) has grown in rece

84 The success of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors (PARPi

85 Poly(ADP-ribose) polymerase-1 (PARP-1) is a zinc finger

86 Poly(ADP-ribose) polymerase-1 (PARP-1) is activated duri

87 Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nu

88 We show here that Poly(ADP-ribose) polymerase-1 (PARP-1) regulates TGF-bet

89 Massive poly(ADP-ribose) formation by poly(ADP-ribose) polymerase-1 (PARP-1) triggers NAD depl

90 PAH-PASMCs have increased the activation of poly(ADP-ribose) polymerase-1 (PARP-1), a critical enzym

91 poly(ADP-ribosyl)ation (i.e., PARylation) of poly(ADP-ribose) polymerase-1 (PARP-1), a multifunctiona

92 Poly(ADP-ribose) polymerase-1 (PARP-1), a ubiquitous and

93 yrin repeat-containing protein that mediates poly(ADP-ribose) polymerase-1 (PARP-1)-dependent transcr

94 IL-1, controls gene expression by activating poly(ADP-ribose) polymerase-1 (PARP-1).

95 is catalytic activation of a nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1).

96 of DNA damage, neuroinflammation, increased poly(ADP-ribose) polymerase-1 (PARP1) activity, single-c

97 actors necessary for iPSC generation, namely poly(ADP-ribose) polymerase-1 (Parp1) and ten-eleven tra

98 he DNA-dependent protein kinase (DNA-PK) and Poly(ADP-ribose) polymerase-1 (PARP1) are critical enzym

99 physiological activity of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP1) causes neuron deat

100 Poly(ADP-ribose) polymerase-1 (PARP1) plays critical rol

101 ss of dopaminergic neurons via activation of poly(ADP-ribose) polymerase-1 (PARP1).

102 This was linked to suppressed poly(ADP-ribose) polymerase-1 activity and was reversibl

103 is able to recruit the transcription factors poly(ADP-ribose) polymerase-1 and splicing factor prolin

104 DP-ribose) in cerebellar neurons, supporting poly(ADP-ribose) polymerase-1 upregulation.

105 cells was linked to defective degradation of poly(ADP-ribose) polymerase-1.

106 Herein, we demonstrate that poly(ADP-ribose)polymerase-1 (PARP-1) is a genome-wide e

107 repair; we found that salidroside activated poly(ADP-ribose)polymerase-1 (PARP-1), a component of th

108 e synthesized and evaluated as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

109 c chromatin condensation as well as distinct poly(ADP-ribose)polymerase-1 cleavage.

110 Poly(ADP-ribose) polymerase-13 (PARP13/ZAP/ZC3HAV1) is a

111 e L1 endonuclease trigger the recruitment of poly(ADP-ribose) polymerase 2 (PARP2) to L1 integration

112 Interestingly, miR-149 inhibits poly(ADP-ribose) polymerase-2 (PARP-2) and so increased

113 Poly(ADP-ribose) polymerase-2 (PARP-2) is one of three h

114 Here we show that Poly(ADP-ribose) polymerase-2 (Parp-2) plays an essentia

115 and RAD50 as suppressors and 53BP1, DDB1 and poly(ADP)ribose polymerase 3 (PARP3) as promoters of chr

116 Increasing evidence define Poly(ADP-ribose) polymerase 3 (PARP3, also known as ARTD

117 However, poly(ADP-ribose) polymerase, a protein involved in DNA r

118 involved in apoptosis (cleaved caspase-3 and poly(ADP-ribose)polymerase), acetylation of tumor suppre

119 increase in caspase-3, cytochrome c release, poly(ADP-ribose) polymerase activation, down-regulation

120 including HMGN1 and RFC1; and regulation of poly(ADP-ribose) polymerase activity.

121 lies of enzymes consume NAD(+) as substrate: poly(ADP-ribose) polymerases, ADP-ribosyl cyclases (CD38

122 ROS and poly(ADP-ribose) polymerase also reduce sirtuin, PGC-1al

123 these conditions correlates with cleavage of poly(ADP-ribose) polymerase, an indicator of apoptosis.

124 e-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.

125 is (p53, Fas, and MST1), DNA damage control (poly(ADP)-ribose polymerase and ataxia telangiectasia mu

126 1-XPF endonuclease in cooperation with PARP1 poly(ADP-ribose) polymerase and RPA The novel gap format

127 at includes elevated CD38 NADase and reduced poly(ADP-ribose) polymerase and SIRT1 activities, respec

128 P-ribose) (pADPr) can be rapidly produced by poly(ADP-ribose) polymerases and degraded by poly(ADP-ri

129 ase and cleavage of caspases 3, 8, and 9 and poly(ADP ribose) polymerase, and suppressed survivin, my

130 Western blotting for the cleaved fragment of poly(ADP-ribose) polymerase, and the active isoform of c

131 y reduced cleavage of caspase-3, -8, and -9, poly(ADP-ribose) polymerase, and the externalization of

132 hibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically ap

133 ed to modulation of Bax, Bcl2, caspase-9 and poly(ADP-ribose) polymerase as well as Reactive Oxygen S

134 f the DNA damage marker gammaH2AX as well as poly(ADP-ribose) polymerase cleavage were elevated in SM

135 poptosis, as assessed by caspase-3 activity, poly(ADP-ribose) polymerase cleavage, phosphatidylserine

136 sitive Annexin V staining and an increase of poly(ADP-ribose) polymerase cleavage.

137 h the AHR target gene TiPARP (TCDD-inducible poly(ADP-ribose) polymerase) contributes to TCDD suppres

138 responses through its N-terminal region in a poly(ADP-ribose) polymerase-dependent manner.

139 PARP-2 is a member of the poly(ADP-ribose) polymerase family, with some activities

140 sis (cleaved CASP8/3 [caspase-8/3] and PARP [poly(ADP-ribose) polymerase] formation).

141 s are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of

142 golipids promoted cell death and cleavage of poly(ADP-ribose) polymerase in cardiomyocytes.

143 eflected by caspase-3/7 activity and cleaved poly(ADP-ribose) polymerase, in different cell lines tha

144 so enhanced ADP-ribosylation and did so by a poly(ADP-ribose) polymerase-independent mechanism.

145 ability, hypersensitivity to DNA damage, and poly(ADP-ribose) polymerase inhibition associated with A

146 rate alpha-ketoglutarate or treatment with a poly(ADP ribose) polymerase inhibitor protects reductive

147 tions initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; h

148 Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is a

149 IEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance

150 The poly(ADP-ribose) polymerase inhibitor olaparib has shown

151 at CHD4-depleted cells are more sensitive to poly(ADP-ribose) polymerase inhibitor treatment.

152 Our data, together with the advent of poly(ADP-ribose) polymerase inhibitor trials, supports t

153 Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer ac

154 Veliparib, an oral poly(ADP-ribose) polymerase inhibitor, has been shown to

155 gagement of the chemotherapeutic Olaparib, a poly(ADP-ribose) polymerase inhibitor, in live cells and

156 cells with mutant p53 were resistant to the poly(ADP-ribose) polymerase inhibitor, veliparib (2-[(2R

157 reaks (DSBs), and increased sensitivity to a poly(ADP-ribose) polymerase inhibitor.

158 ard in three steps to produce veliparib 1, a poly(ADP-ribose) polymerase inhibitor.

159 y, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor.

160 tion forks is a prominent mechanism of PARP (Poly(ADP-ribose) Polymerase) inhibitor (PARPi) resistanc

161 Poly(ADP ribose) polymerase inhibitors (PARPi) have effi

162 uely responsible for cellular sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi) in BRCA1-

163 Poly(ADP-ribose) polymerase inhibitors (PARPi) selective

164 annot perform HDR, conferring sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi).

165 t samples, RITA, AF, and Onc-1 sensitized to poly(ADP-ribose) polymerase inhibitors both in vitro and

166 2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation

167 Although poly(ADP-ribose) polymerase inhibitors have shown promis

168 rt expansion of the treatment indication for poly(ADP-ribose) polymerase inhibitors to include patien

169 nt kinases 4 and 6, angiogenesis inhibitors, poly(ADP-ribose) polymerase inhibitors, as well as chemo

170 In response to DNA damage induced by poly(ADP-ribose) polymerase inhibitors, CHD4 deficiency

171 cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors.

172 ation) activity and is affected by canonical poly(ADP-ribose) polymerase inhibitors.

173 and sensitizes cells to DNA crosslinkers and poly(ADP-ribose) polymerase inhibitors.

174 d DNA damage-repair-targeting agents such as poly(ADP-ribose)-polymerase inhibitors.

175 The vault-interacting domain of vault poly(ADP-ribose)-polymerase (INT) has been used as a shu

176 ated that, besides direct cytotoxic effects, poly(ADP ribose) polymerase (PARP) inhibitors (PARPis) e

177 ance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP) inhibitors.

178 w that ATAD5-depleted cells are sensitive to poly(ADP)ribose polymerase (PARP) inhibitors and that th

179 l series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.

180 modification is catalyzed mainly by nuclear poly(ADP-ribose) polymerase (PARP) 1 in response to DNA

181 t its chromatin accumulation was enhanced in poly(ADP-ribose) polymerase (PARP) 1(-/-) compared with

182 nM), we observed loss of CIPs and increased poly(ADP-ribose) polymerase (PARP) activation [also obse

183 We found that poly(ADP-ribose) polymerase (PARP) activation distinguis

184 (COX-2 and IL-1beta) and apoptotic markers (poly(ADP-ribose) polymerase (PARP) and caspase 3).

185 Poly(ADP-ribose) polymerase (PARP) and poly(ADP-ribose)

186 emonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors i

187 n BC3 and BCBL1 PEL cells but did not induce poly(ADP-ribose) polymerase (PARP) cleavage in virus-neg

188 hylation, induction of autophagy, and robust poly(ADP-ribose) polymerase (PARP) cleavage indicative o

189 hrome c release, activation of caspases, and poly(ADP-ribose) polymerase (PARP) cleavage.

190 vidence is provided that the activity of the poly(ADP-ribose) polymerase (Parp) enzyme is required fo

191 Prior work has established that the poly(ADP-ribose) polymerase (PARP) enzyme Tankyrase (TNK

192 ants into nucleosomes, and activation of the poly(ADP-ribose) polymerase (PARP) enzyme.

193 The poly(ADP-ribose) polymerase (PARP) enzymes were initiall

194 e a critical function of some members of the poly(ADP-ribose) polymerase (PARP) family in clearance o

195 The mammalian poly(ADP-ribose) polymerase (PARP) family includes ADP-r

196 rences are seen between tankyrases and other poly(ADP-ribose) polymerase (PARP) family members.

197 ld, leading the way for the discovery of the poly(ADP-ribose) polymerase (PARP) family of enzymes and

198 Members of the poly(ADP-ribose) polymerase (PARP) family of enzymes are

199 Tankyrases 1 and 2 are members of the poly(ADP-ribose) polymerase (PARP) family of enzymes tha

200 The poly(ADP-ribose) polymerase (PARP) family of proteins us

201 ly(ADP-ribosyl)ated and that mutation of the poly(ADP-ribose) polymerase (Parp) gene impairs their fu

202 Inhibitors of poly(ADP-ribose) polymerase (PARP) have demonstrated eff

203 highly toxic DNA strand breaks that trigger poly(ADP-ribose) polymerase (Parp) hyperactivation, cell

204 Synthetic lethality between poly(ADP-ribose) polymerase (PARP) inhibition and BRCA d

205 nfer cellular sensitization to radiation and poly(ADP-ribose) polymerase (PARP) inhibition.

206 t led to the automated radiosynthesis of the poly(ADP-ribose) polymerase (PARP) inhibitor [(18)F]olap

207 Further, we observed that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib sy

208 ion of BRCA2, could help select patients for poly(ADP-ribose) polymerase (PARP) inhibitor or platinum

209 DNA damage, BRCA1 localization to DSBs, and poly(ADP-ribose) polymerase (PARP) inhibitor resistance.

210 ng agents melphalan and cisplatin and to the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (

211 Methods: Using a radiolabeled poly(ADP-ribose) polymerase (PARP) inhibitor, (125)I-KX1

212 We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined w

213 Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previo

214 9 rendered GLS(high) cells vulnerable to the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib,

215 nction and was recently reported as a potent poly(ADP-ribose) polymerase (PARP) inhibitor.

216 and breaks and disruption of this pathway by Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) is

217 understanding acquired tumour resistance to poly(ADP-ribose) polymerase (PARP) inhibitors and other

218 RCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platin

219 Poly(ADP-ribose) polymerase (PARP) inhibitors are increa

220 Bevacizumab and maintenance poly(ADP-ribose) polymerase (PARP) inhibitors both signi

221 Poly(ADP-ribose) polymerase (PARP) inhibitors can genera

222 Poly(ADP-ribose) polymerase (PARP) inhibitors have activ

223 Poly(ADP-ribose) polymerase (PARP) inhibitors have shown

224 eterogeneous responses to platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors in clinica

225 ical trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in patient

226 In the present study we observed that the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib a

227 ression levels show increased sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, especiall

228 eutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due

229 fold is an important structural motif of new poly(ADP-ribose) polymerase (PARP) inhibitors, playing a

230 tizes tumors to DNA cross-linking agents and poly(ADP-ribose) polymerase (PARP) inhibitors, we sought

231 Thus, poly(ADP-ribose) polymerase (PARP) inhibitors, which dis

232 provide insight into why clinical trials of poly(ADP-ribose) polymerase (PARP) inhibitors, which req

233 DNA-damaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors.

234 compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors.

235 o known as EWSR1)-FLI1 gene translocation to poly(ADP-ribose) polymerase (PARP) inhibitors.

236 ian cancer but also creates vulnerability to poly(ADP-ribose) polymerase (PARP) inhibitors.

237 (T-ALL) cells exhibit a high sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors.

238 A1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors.

239 Poly(ADP-ribose) Polymerase (PARP) is a family of enzyme

240 Poly(ADP-ribose) polymerase (PARP) is implicated in DNA

241 Activation of poly(ADP-ribose) polymerase (PARP) near sites of DNA bre

242 This study explores the role of poly(ADP-ribose) polymerase (PARP) on global gene expres

243 Poly(ADP-ribose) polymerase (PARP) superfamily members c

244 Human tankyrase-1 (TNKS) is a member of the poly(ADP-ribose) polymerase (PARP) superfamily of protei

245 ication effected by enzymes belonging to the poly(ADP-ribose) polymerase (PARP) superfamily, mainly b

246 The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and T

247 e in colorectal cancer by interacting with a poly(ADP-ribose) polymerase (PARP) tankyrase.

248 Tankyrase 1 is a poly(ADP-ribose) polymerase (PARP) that participates in

249 ed caspase 3, cleaved caspase 9, and cleaved poly(ADP-ribose) polymerase (PARP), suggesting that impa

250 ed by inhibition of the NAD-consuming enzyme poly(ADP-ribose) polymerase (PARP)-1 or supplementation

251 while p65NF-kappaB phosphorylation, cleaved poly(ADP-ribose) polymerase (PARP)-1, and cyclooxygenase

252 er at their C termini: ZAPL (long) encodes a poly(ADP-ribose) polymerase (PARP)-like domain that is m

253 of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP).

254 n of Gli1 and an increase in the cleavage of poly(ADP-ribose) polymerase (PARP).

255 onal activator, heat shock factor (HSF), and poly(ADP-ribose) polymerase (PARP).

256 damage by inhibiting the DNA repair protein poly(ADP-ribose) polymerase (PARP).

257 ed caspase-3, cleaved caspase-7, and cleaved poly(ADP-ribose) polymerase (PARP).

258 ivo, we show that the anti-apoptotic protein poly(ADP-ribose) polymerase (PARP)14 promotes aerobic gl

259 ediated apoptosis by affecting expression of poly(ADP-ribose) polymerase (PARP)14, a key regulator of

260 e minutes) through mechanisms that depend on poly(ADP-ribose) polymerases (PARP) and the catalytic su

261 Poly(ADP-ribose) polymerases (PARP) attach poly(ADP-ribo

262 r targets are the tankyrase proteins (TNKS), poly(ADP-ribose) polymerases (PARP) that regulate Wnt si

263 Poly(ADP-ribose)-polymerase (PARP)-1 and PARP-2 play an

264 The enzyme poly(ADP-ribose)polymerase (PARP) has a dual function be

265 ficiency, as measured by hypersensitivity to polyADP-ribose polymerase (PARP) inhibition.

266 pendent on mono-ADP ribosylation activity of poly(ADP-ribose) polymerase (PARP1).

267 The poly(ADP-ribose) polymerases (PARPs) and histone deacety

268 The poly(ADP-ribose) polymerases (PARPs) are a major family

269 Poly(ADP-ribose) polymerases (PARPs) are involved in DNA

270 al modification, is immediately catalyzed by poly(ADP-ribose) polymerases (PARPs) at DNA lesions, whi

271 unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical be

272 longing to the tankyrase (Tnks) subfamily of poly(ADP-ribose) polymerases (PARPs) have recently been

273 Poly(ADP-ribose) polymerases (PARPs) synthesize and bind

274 posttranslational modification catalyzed by poly(ADP-ribose) polymerases (PARPs) that mediate EBV re

275 It forms DNA adducts, thereby activating poly(ADP-ribose) polymerases (PARPs) to initiate DNA rep

276 posttranslational modification catalyzed by poly(ADP-ribose) polymerases (PARPs) using NAD(+) as ADP

277 Poly(ADP-ribose) polymerases (PARPs), enzymes that modif

278 poly(ADP-ribose) glycohodrolases (PARGs) and poly(ADP-ribose) polymerases (PARPs).

279 rate of tankyrases, which are members of the poly(ADP-ribose) polymerases (PARPs).

280 ising targets in anticancer therapy, are the poly(ADP-ribose) polymerases (PARPs).

281 sed apoptosis characterized by caspase 3 and poly(ADP-ribose) polymerase processing, DNA cleavage, an

282 ch damages DNA and causes hyperactivation of poly(ADP-ribose) polymerase, resulting in extensive NAD(

283 otein PNKP and implicates hyperactivation of poly(ADP-ribose) polymerase/s as a cause of cerebellar a

284 ates for several NAD-consuming enzymes (e.g. poly(ADP-ribose) polymerases, sirtuins, and others).

285 Resolution at telomeres requires the poly(ADP-ribose) polymerase tankyrase 1, but the mechani

286 the histone variant macroH2A1.1 binds to the poly(ADP-ribose) polymerase tankyrase 1, preventing it f

287 n be induced by inhibition of tankyrase 1, a poly(ADP-ribose) polymerase that is required for resolut

288 Tankyrase 1 and 2 are poly(ADP-ribose) polymerases that function in pathways c

289 Tankyrases are poly(ADP-ribose) polymerases that have many cellular fun

290 lation of downstream effector TCDD-inducible poly(ADP-ribose) polymerase (TiPARP) during infection.

291 tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly(ADP-ribose) polymerase (TiPARP) gene expression, de

292 ere, we show that the loss of TCDD-inducible poly(ADP-ribose) polymerase (Tiparp), an ADP-ribosyltran

293 AhR repressor (Ahrr/AhRR) and TCDD-inducible poly(ADP-ribose)polymerase (Tiparp/TiPARP) by AhR ligand

294 se 3 and cleavage of the caspase 3 substrate poly(ADP-ribose) polymerase were inhibited in E. faecali

295 rker proteins, cleaved caspase 7 and cleaved poly(ADP-ribose) polymerase, were significantly reduced

296 Various poly(ADP-ribose) polymerases which are notorious guardia

297 This activates nuclear poly(ADP-ribose) polymerase, which inhibits GAPDH, shunt

298 ncer cells and decreases the level of intact poly(ADP-ribose) polymerase, which is indicative of apop

299 DNA damage was associated with activation of poly(ADP-ribose) polymerase, which led to consumption of

300 AD precursors, exercise regimens, or loss of poly(ADP-ribose) polymerases yet surprisingly do not exh